Drug Trial Radar · NCT03929666
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Aug 22, 2019
Primary completion
Aug 30, 2025
Study completion Aug 30, 2025
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- First posted
- Apr 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC).
Conditions
- HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Interventions
ZW25 (Zanidatamab)Drug
* Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC) * Part 2: RD identified in Part 1
CapecitabineDrug
Administered orally twice daily (PO bid)
CisplatinDrug
Administered IV
FluorouracilDrug
Administered IV
LeucovorinDrug
Administered IV
OxaliplatinDrug
Administered IV
BevacizumabDrug
Administered IV
GemcitabineDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Dose-limiting Toxicities (DLTs) (Part 1)Time frame: Cycle 1 of treatment for all Part 1 treatment regimens (each cycle is 21 days for the XELOX, FP, and CisGem regimens; 28 days for the mFOLFOX6 regimens)
- Number of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
- Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
- Confirmed Objective Response Rate (ORR) (Parts 1 and 2)Time frame: From time from confirmed best response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
H. Lee Moffitt Cancer Center
Tampa, Florida
University of Chicago
Chicago, Illinois
The Cancer and Hematology Centers
Grand Rapids, Michigan
Nebraska Methodist Hospital
Omaha, Nebraska
Memorial Sloan Kettering Cancer Center
New York, New York
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Virginia Mason Medical Center
Seattle, Washington
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Centro de Investigacion Clinica SAGA
Santiago, Chile
Icegclinic Research & Care
Santiago, Chile
CECIM Biocinetic
Santiago, Chile
Centro Internacional de Estudios Clínicos
Santiago, Chile
Pusan National University
Busan, South Korea
Korea University Anam Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.